key: cord-0797559-r7y849q4
authors: Lima, Rafael Silva; Rocha, Luiz Paulo Carvalho; Moreira, Paula Rocha
title: Genetic and epigenetic control of ACE2 expression and its possible role in COVID‐19
date: 2021-06-01
journal: Cell Biochem Funct
DOI: 10.1002/cbf.3648
sha: a587cfe39b21a13c0609720576dba958a7334970
doc_id: 797559
cord_uid: r7y849q4

Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), is a pandemic that is claiming hundreds of thousands of lives around the world. Angiotensin‐converting enzyme‐2 (ACE2) is a key player in COVID‐19 due to its pivotal role in the SARS‐CoV‐2 infection. This enzyme is expressed throughout the body and the studies conducted so far have shown that its expression varies according to several factors, including cell type, sex, age, disease states and probably SARS‐CoV‐2 infection. Single‐nucleotide polymorphisms (SNPs) and epigenetic mechanisms, including DNA methylation, histone post‐translational modifications and microRNAs, impact ACE2 expression and may explain structural variation. The understanding of how genetic variants and epigenetic markers act to control ACE2 expression in health and disease states may contribute to comprehend several aspects of COVID‐19 that are puzzling researchers and clinicians. This review collects and appraises the literature regarding some aspects in the ACE2 biology, the expression patterns of this molecule, SNPs of the ACE2 gene and epigenetic mechanisms that may impact ACE2 expression in the context of COVID‐19.

Coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a disease that spread quickly from its epicentre in Wuhan, a city located in the Chinese province of Hubei, reaching 1 million confirmed cases worldwide on 2 April 2020, with an estimated death rate of 5.2%. 1 One of the key features of the infection -and that explains its widespread -is its high interpersonal transmissibility. Interhuman transmission has been identified via droplets, direct contact and indirect contact through surfaces. 2 Moreover, the virus has been identified in blood, saliva and stool. [3] [4] [5] Another important characteristic of the virus is its resistance in the external environment: it can remain viable on plastic surfaces for up to 3 days. 6 Once in contact with healthy cells, SARS-CoV-2 can use the renin-angiotensin system enzyme angiotensin-converting enzyme-2 (ACE2) along with the transmembrane protease serine type-2 (TMPRSS2), which are anchored on the cell membrane, to enter and continue the infection. 7 Because not every cell and tissue express these enzymes, the virus cannot attack all tissues or organs indistinctly. In addition to this difference in susceptibility in the context of the organs of the same individual, there is a marked discrepancy in the susceptibility levels of different patients: men, elders and patients with prior history of cardiovascular, pulmonary and metabolic diseases constitute the population with a higher risk of severe and lethal disease. 8, 9 On the other extreme, a large proportion of the individualsperhaps the great majority of infected subjects -are asymptomatic. 10 The factors that account for this differential susceptibility are not fully understood yet. Nevertheless, the study of ACE2 is undoubtfully of great importance to shed light on some of the open questions.

Given the importance of ACE2 for the present pandemic, this review will explore the characteristics of ACE2, the genetic and epigenetic control of the ACE2 gene and its possible impact in the context of COVID-19. Our intent in the elaboration of this review was to better comprehend some features of ACE2 and point out new and promising research fields in COVID-19.

ACE2 was discovered in 2000, as two independent groups characterized a carboxypeptidase homologue of the well-known ACE that could cleave angiotensin I and angiotensin II and was not inhibited by conventional ACE inhibitors, such as captopril, lisinopril and enalaprilat. 11, 12 The ACE2 gene is located in chromosome X position p22 and comprises approximately 40 kb, containing 18 exons intercalated with 17 introns. 12 Interestingly, it was reported that this region could escape X inactivation in female cells, although higher expression was seen in males in some tissues. 13 In addition to this, several singlenucleotide polymorphisms (SNPs) have been found in ACE2. 14, 15 ACE2 is a type I transmembrane, 805 amino acids-long glycoprotein that contains a short C-terminal intracellular tail and an N-terminal that extends to the extracellular space and contains the peptidase domain (PD) of the enzyme. 11, 12 ACE2 and the testicular ACE share 33% of the amino acids and both enzymes have a conserved region in the active site: the zinc-binding motif His-Glu-Met-Gly-His. 11 ACE2 is a strict monocarboxypeptidase and contains a single active site. 11, 16 ACE2 can also be detached from the plasma membrane through the action of disintegrin and metalloproteinase domain-containing protein 17 (ADAM-17), induced by angiotensin II. 17 ACE2 cleaves angiotensin II and angiotensin I -the latter much less efficiently than angiotensin II -into angiotensin (1-7) and angiotensin (1-9), respectively. 11, 16 Through its action, ACE2 reduces the availability of angiotensin II and produces angiotensin (1-7), which acts on the Mas receptor (MasR) inhibiting diuresis and inducing vasodilation and vasoprotection. 18, 19 Given the cardiovascular protective properties of the peptides produced through the action of ACE2, especially angiotensin (1-7), it may be important to maintain ACE2 expression or activity in the context of COVID-19.

In addition to counterbalancing the action of ACE and angiotensin II, ACE2 has two other physiological roles: the cleavage of apelin peptides and the formation of an amino acid transporter along with SLC6A19. 20 Apelin is a peptide, comprised of 77 amino acids, that is cleaved by endopeptidases to give rise to several smaller peptides whose activity through the G protein-coupled receptor angiotensin II protein J receptor (APJR) mediates important protective actions in the cardiovascular system. 21, 22 ACE2 is able to remove the C-terminal amino acids from these peptides and, at least, partially inactivate them given the lower hypotensive action in the presence of ACE2, whereas the ACE2 deficiency or inhibition or the introduction of apelinresistant analogs rescued the cardioprotective effects of the peptides. 23 However, the metabolized apelin peptides may also be biologically relevant. 24 Remarkably, apelin peptides specifically induce ACE2 expression through the action of APJR. 25 Given its actions, it has been hypothesized that apelin, and possibly its ACE2-metabolized peptides, may be protective in COVID-19 through their cardioprotective mechanisms. 26 ,27 ACE2 has been found associated with SLC6A19 in the brush border of epithelial intestinal cells and the proximal kidney tubules. 28, 29 SLC6A19 is expressed in the kidney and in the small intestine, where it mediates the transport of neutral amino acids from the lumen to the interstice. 29 Whereas it partners with collectrin and ACE2 in the kidney, it relies exclusively on ACE2 in the intestine, forming a dimer of heterodimers. 30, 31 Although SARS-CoV-2 can bind to ACE2 in the presence of SLC6A19 when the complex is in a closed state, 31 it was not determined yet if the presence of the amino acid transporter alters the dynamics of interaction or internalization.

Following the onset of the COVID-19 pandemic, ACE2 was readily recognized as the receptor for SARS-CoV-2 entry. 7,32 Like SARS-CoV, SARS-CoV-2 has a spike (S) protein, which is a trimeric protein composed of S1 and S2 domains both with high homology, mainly in the receptor-binding domain (RBD) -73.9% of the residues are similar between the viruses. 33, 34 Before interacting with ACE2, the priming of the S protein is necessary and achieved by proteases, like TMPRSS2 and cathepsin L/B. 7 The S protein of SARS-CoV-2, specifically, is also cleaved by furin at the S1/S2 boundary, which enhances the virus entry in susceptible cells if compared to SARS-CoV, which does not rely on this mechanism. 35, 36 After cleavage, the C-terminal domain (CTD) of S1 is exposed and ready to make contact with the outer surface of the PD of ACE2. 33, 37 Both SARS-CoV and SARS-CoV-2 have a CTD structure composed of a core subdomain bearing five antiparallel β-strands and an external subdomain composed of two β-strands connected by a flexible loop. 33, 38 The contact of the CTD of S1 and ACE2 is mediated mainly by the external subdomain and is driven by polar interactions -H bonds -between the viral and the human proteins. 33, 38 Despite the similarities between the RBDs of the two viruses, ACE2 has a stronger affinity for that of SARS-CoV-2 due to key substitutions in its RBD. 31, 33 Moreover, the epitopes displayed in the RBDs of the two proteins are different, which could explain why antibodies targeting the RBD of one virus do not block the infection caused by the other. 33, 39 Bioinformatics predictions have pointed to different directions: while it was reported that some variants of ACE2 could bind to the RBD of SARS-CoV-2 with varying affinities and thereby be protective against the infection or favour it, 40,41 another study did not find any difference the interaction considering eight variants found in European non-Finnish and African populations. 42 An in vitro study testing ACE2 variants did not found any evidence for their role in modulating the interaction with SARS-CoV-2, except for one that reduced the expression of ACE2. 43 The relevance of these results in vivo, however, remains to be studied.

In the seminal papers characterizing ACE2, its expression determined by Northern-blotting was tracked in higher levels in the kidney, heart and testis, but lower levels were detected in the colon, small intestine and ovary. 12, 13 Later, the mRNA expression was determined by qRT-PCR across 72 tissues from three donors. It was shown that ACE2 is ubiquitously expressed, but higher levels were seen in the testis, kidney, digestive tract and cardiovascular tissues. Interestingly, the highest expression was observed in the ileum. 44 Following the SARS epidemic, immunohistochemical localization of the ACE2 protein revealed specificity in the localization of the protein within several tissues. Positive staining was found in endothelial cells and smooth muscle in the cardiovascular system; epithelial cells from the proximal tubules of the kidney; in alveolar type 1 and 2 (AT1 and AT2, respectively) epithelial cells in the lungs; in the smooth muscle and enterocytes in the gut; in the basal layer of the skin and oral and nasal mucosa and marginal staining was described in the brain. 45 Recent studies employing single-cell transcriptome analysis and looking at transcriptome databases have described interesting results that could help to explain the entry and tropism of SARS-CoV-2. Consistent with prior literature, epithelial and endothelial cells of the intestine are the main cell types expressing ACE2 mRNA, with the ileum and colon presenting the highest proportion of positive cells. [46] [47] [48] [49] Considering the oral cavity, which is an important entry site for the virus, the tongue holds epithelial cells, lymphocytes and fibroblasts expressing ACE2. 48 In the superior airways, ACE2 expression was observed in secretory epithelial cells of the nasal and sinus mucosa. 50 Tracheal epithelial cells, large airway epithelial cells and, in a smaller proportion, small airway epithelial cells (SAE) express ACE2 mRNA. 51 In the lungs, AT2 cells are the main cell type expressing both ACE2 and TMPRSS2. 51, 52 In addition to these, transient secretory cells, a cell type that expresses markers of Goblet and ciliated cells, also presented high expression of ACE2 and TMPRSS2. 52 In addition, FURIN expression was observed in lung cells, often being expressed in the ACE2 + and TMPRSS2 + cells. 52 In the heart, pericytes are the main cells expressing ACE2. It was shown that these cells establish interactions with endothelial cells, which could promote microcirculatory dysfunctions in the heart if the virus is present. 46 In the urinary tract, epithelial cells of the proximal tubules and the urothelial cells of the bladder were observed expressing the enzyme. 49 In testes, particularly, spermatogonia, leydig and sertoli cells -these two cell populations could not be separated in this study -were shown expressing ACE2, with spermatogonia also expressing TMPRSS2. 53 Neuronal expression was also reported based on data from transcriptome databases and animal studies. [54] [55] [56] Considering the data presented, it could be hypothesized that the organs with the highest expression could be the most affected by the disease and the infection routes comprise the oral and nasal mucosa. Indeed, it is known that gastrointestinal, pulmonary, cardiovascular and renal symptoms are common in COVID-19 patients and the use of face masks greatly reduces transmission. 57, 58 However, the scenario seems to be more nuanced, as multi-organ failure and multisystem inflammatory syndrome in children in the context of COVID-19 reveal that, in addition to cytopathic effects directly attributable to the virus infecting the cells through ACE2, immune activation, cytokine storm, endothelial dysfunction and the coagulopathy that follows the infection contributes to damage and its manifestations. [59] [60] [61] In addition to the cell type, several factors have been described to modulate the expression of ACE2. Studies observed modulation of ACE2 expression by age and sex in animal models and humans. Elder rats (24-month old) presented lower protein expression compared to young and middle-aged (3-and 12-month old) in the lungs. Moreover, elder females showed higher expression than males. 62 In sheep, males experienced increased ACE2 activity from birth to the first year and 1-year-old animals of both sexes displayed increased protein and mRNA expression compared to newborn lambs. 63 In mice, gonadectomy increased the activity of renal ACE2 in females only, and treatment with 17β-estradiol decreased the activity of the enzyme in both males and females regardless of the sex chromosome complement. 64 Normal human bronchial epithelial cells grown at an air-liquid interface treated with 17β-estradiol also displayed lower ACE2 mRNA expression than vehicle-treated controls. 65 In humans, the analysis of transcriptomic datasets has revealed that ACE2 is differentially expressed in the nasal and bronchial cells between children and adults and in some tissues between men and women, with adults and men having higher expression. 13, 66 Using qPCR, it was also shown that age is positively correlated with ACE2 mRNA expression in a cohort including patients with respiratory disease and that sex and age are significantly associated with ACE2 expression in a multivariate analysis. 67 In combination with sex, smoking was reported to increase ACE2 and TMPRSS2 mRNA in SAE cells, with male smokers having a higher expression of ACE2 compared to female smokers. 51 These data suggest that older people, males and smokers are at higher risk for SARS-CoV-2 infection and mortality. Several meta-analyses revealed that males, and particularly older patients are at higher risk for infection and mortality regardless of ethnicity. [68] [69] [70] [71] [72] However, the evidence for smoking is controversial, although it favours the case of smoking as a risk factor. [73] [74] [75] Hypoxia is also a factor that modulates ACE2 expression and may be an important risk factor for complications following COVID-19.

HIF-1α, a key transcription factor involved in the hypoxia response and that was found to be upregulated in the peripheral blood of COVID-19 patients. 76 HIF-1α has been observed to downregulate ACE2 mRNA and protein in airway smooth muscle and umbilical vein endothelial cells. 77, 78 Consistently with these findings, patients with lung fibrosis, a condition that is associated with the hypoxic state, display lower ACE2 expression. 79 This ACE2 downregulation promoted by HIF-1α may cause dysregulation of the concentration of the protective peptides derived from the action of this enzyme. 80 Moreover, HIF-1 upregulation following hypoxia may trigger inflammatory signalling. 76 However, ACE2 increased expression was observed in the culture of hepatocarcinoma cells under prolonged hypoxia and asthmatic patients have no difference in ACE2, TMPRSS2 and FURIN expression in the epithelial brush border cells compared to healthy controls, which suggests that hypoxia and pulmonary diseases may induce different responses according to the cell type and the duration of the stimulus. 81, 82 Hyperoxia, in its turn, was involved in ACE2 activity downregulation through its shedding promoted by ADAM-17. 83 The metabolic status also has an influence on ACE2, since type I and II diabetes mellitus were shown to modulate ACE2 activity and expression in humans and mice. [84] [85] [86] [87] [88] Inflammation may also play a role in ACE2 expression, since NF-κB, IFN-γ and TNF-α, IL-1β, IL-4 and TGF-β may regulate it. 82, [89] [90] [91] Conversely, ACE2 may also regulate inflammation and thrombus formation, particularly in the context of SARS-CoV-2 infection. 92 Heart failure has been associated with increased ACE2 activity and expression, perhaps due to a compensatory mechanism. While angiotensin II may induce further cardiac damage, increased ACE2 means higher levels of angiotensin (1-7), which is cardioprotective. 18, [93] [94] [95] The pharmacological induction of ACE2 expression was also reported. Agents that can modulate ACE2 are ACE inhibitors (ACEI), angiotensin II AT1 receptor blockers (ARBs), statins, mineralocorticoid antagonists and rosiglitazone. [96] [97] [98] [99] [100] Nevertheless, the discontinuation of these drugs in patients infected with SARS-CoV-2 is a matter of debate. 101, 102 In the SARS-CoV-2 infection, it is possible that ACE2 protein expression is downregulated, as is the case in the SARS-CoV infection. 103 Particularly in the latter, the viral S protein alone was able to decrease the levels of ACE2 protein expressed in the cell membrane, probably due to the internalization of the molecule, and worsen acute lung injury in acid-challenged mice. 103 Indeed, a recent study has shown that platelets reduce their ACE2 membrane expression due to internalization when facing the virus or its S protein. Moreover, virus-activated platelets exhibit higher aggregatory capacity and inflammatory cytokine release, which could explain some of the thromboembolic events in COVID-19. 104 It was also reported that SARS-CoV-2 infection in the lung cancer cell line Calu-3 slightly decreased ACE2 mRNA expression through the upregulation of the transcriptional repressor zinc finger E-box-binding homeobox 1 (ZEB1). 105 As Verdecchia et al. (2020) discuss in their review, this ACE2 downregulation may have adverse cardiopulmonary effects in COVID-19, since Angiotensin II would accumulate, and Angiotensin 1-7 levels would be decreased. 106 A potentially beneficial approach to rescue ACE2 loss in infected patients would be the treatment with recombinant human ACE2 protein (rhACE2) or an antibody targeting the S protein. 104, 107 Currently, there is one completed clinical trial studying rhACE2 as a treatment for COVID-19 (NCT04335136).

Additionally, a case report observed decreased concentration of inflammatory cytokines, reduced the presence of SARS-CoV-2 in plasma and airways, and clinical recovery following the administration of soluble rhACE2. 108 

Polymorphic variants may be responsible for altering levels and patterns of expression in different tissues. Also, they can modify the composition and conformation of the protein. 109 The ACE2 gene is one of the genes with the most genetic variants, and some studies have evaluated its relationship with diseases. 109, 110 In the current pandemic, the variability in susceptibility to COVID-19 depends on several factors, and genetic polymorphisms can be one of them. Differences in the spread of the virus, as well as in the development and worsening of symptoms, may be related to the polymorphic genetic variability of the ACE2 gene. 109, 111 The ACE2 gene is located on the chromosome X: Also, we can distinguish 660 missense and synonymous variants. 112 This gene has great potential for genetic variability and this is observed in different populations worldwide. 111 Change of only one nucleotide in the base sequence, in at least 1% of the population, is called SNP. 113 SNPs are common changes that occur in DNA with the potential to modify the observed phenotype and can have an important impact on the epidemiology of some diseases. 114, 115 However, finding this relationship is not an easy task. Few studies have related to the allelic frequency of ACE2 variants with specific changes in the lungs, despite the high levels of expression of this enzyme in alveolar cells. 123 The published works refer to the great susceptibility of the structures that make up the airways to express high levels of ACE2 and consequently increase the risk of infection by SARS-CoV. 14,124 Some variants, like rs2285666, are related to this higher probability in some Asian populations, even so, the studies found it difficult to relate this finding in other populations. 125, 126 Despite this, it has been published on the influence of Angiotensin II bioavailability on pulmonary fibrosis, inflammation and cytokine production, clinical findings commonly seen in patients with COVID-19. 127 Changes in the serum level of angiotensin (1-7) were related to the rs2074192 and rs2106809 variants in the Han population in hypertensive patients, which can influence the involvement of the lungs in patients affected by COVID-19.

The cytokine storm is the most important factor in the worsening and widespread involvement of the organism in the disease. The presence of chronic and acute diseases and comorbidities increases the risk of morbidity and mortality in these patients. 128 Obesity, liver disease and kidney disease are those that stand out in terms of fatality related to COVID-19, followed by chronic obstructive pulmonary disease, cardiovascular diseases, diabetes and hypertension. 122 Some of the effects of these comorbidities have been related to polymorphic variants in some populations. The variants rs1978124, rs2236306, rs233575, rs4646188, rs879922, rs2106809, rs2285666, rs4646142, rs4646155 and rs4646188 were related to changes in low-density and high-density lipoprotein cholesterol levels, and rs2106809 and rs2285666 were related to type 2 diabetes in the Chinese population.

Also, rs2285666, rs4240157, s4646142, rs4646155 and rs4830542 were related to tissue damage in organs like the heart.

Another important factor about ACE2 polymorphisms would be the impact on dissemination and susceptibility to infection. This information is perhaps the most important and difficult to obtain, due to the difficulty of analysing the genotype of a population during a pandemic. 129 Even so, some incipient findings give an idea of the SNPs involved. rs4646127, rs2158082, rs5936011, rs6629110, rs4830983 and rs5936029 are related to greater ACE2 expression and greater susceptibility to COVID-19 in East Asian, European, African, South Asian and mixed American. 130 Besides that, allelic changes in this gene are distributed differently between men and women due to their location on the X chromosome and can interfere with COVID-19 infection. 131, 132 Epidemiological data worldwide show that men are most affected by the pandemic.

They have the highest rates of infection and also the highest rates of morbidity and mortality. 133 Many factors can contribute to this finding, such as cultural behaviour of exposure and self-care, pre-existing diseases, hormonal factors, genetic and phenotypic factors. 134 However, the genetic basis of ACE2 can contribute to this scenario, such as the presence of variants related to diseases or related to increased expression. It was seen that there is a relationship between the increase in the expression of ACE2 and the risk of infection. But once infected, the higher expression of ACE2 may be a factor that contributes to a better prognosis. 135 Although many of the changes related to polymorphic variants are detected in women (Table S1 in Data S1), there is evidence that points to a greater expression of ACE2 in the female gender. 135, 136 This increase in expression may be related to some polymorphic variants.

Evaluations of exon changes are still very incipient, especially with respect to SARS-CoV-2. The most recent publications bring an analysis of bioinformatics about the possibilities of exonic variants. 40, 42 Some candidates have shown to be potential modifiers of the interaction of the viral protein and the ACE2 receptor, but have not yet assessed this change in the field. The data for the variants and polymorphisms can be seen in Table S1 in Data S1.

Epigenetics is the study of the mitotically heritable changes in the gene function that cannot be explained by the changes in the DNA molecule. 137 One important feature of the epigenetic mechanisms is the malleability in face of an environmental change: through the cellular sensors, changes can be transmitted to the machinery involved in writing, reading and erasing these marks. In this way, the cell can adapt its functions to cope with a particular stimulus. 138, 139 DNA methylation is an epigenetic mechanism characterized by the addition of a methyl group in the 5 0 carbon of the cytosine base followed by a guanine (CpG) promoted by the enzymes DNA methyltransferases. 140 ChrX:15,621,814 had higher methylation in the cases than in controls. 142 Additionally, they found that control men and women differed in the methylation levels in the CpGs located at ChrX:15621814 and ChrX:15,621,846. 142 Differential ACE2 methylation and expression were also observed in CD4 + T cells of lupus patients. 143, 144 Finally, it was determined that cancer may modulate ACE2 expression through ACE2 promoter methylation since methylation changes are concordant with the expression in several cancer types. 145 Taken together, these results suggest that ACE2 methylation and expression may be regulated by the intrauterine life, by autoimmune, neoplastic and metabolic diseases, and by sexual factors. Concurrently, with the epidemiological data of the COVID-19 pandemics, these findings may provide some evidence to explain the differences in susceptibility and severity between the sexes and point out diseases like lupus and cancer to be risk factors for the disease. 146, 147 Histone PTMs correspond to the covalent attachment of several organic radicals mainly to the residues of the N-terminal tails that protrude from the octamer of histones that compose the nucleosome. 137 The result of the PTMs can be either repress transcription or allow it depending on the nature of the radical that is added and the residue where it occurs. 139 Rabbits treated with a high-cholesterol diet (HCD) experienced in the heart global reductions of H3S10 phosphorylation Hypoxia upregulates miR-let-7b, which decreases ACE2 expression in cultured cells. miR-let-7b expression depends on HIF-1α, as its inhibition partially prevents miR-let-7b upregulation. miR-let-7b induces cell migration and proliferation, whereas miR-let-7b knockout mice under hypoxic conditions presented higher ACE2 histochemical staining in the pulmonary artery wall, concomitant with thickened artery wall and higher Fulton's index [154] miR-1246 Cell culture (PMVEC), C57Bl/6mice LPS treatment induces miR-1246 upregulation, which downregulates ACE2 expression. LPS upregulates apoptosis, IL-1β and TNF-α through miR-1246, while ACE2 overexpression represses apoptosis. Anti-miR-1246-injected mice presented improved lung injury score, ACE2 expression, vascular permeability and decreased inflammation following intrathecal LPS instillation [155] Small airway epithelial (SAE) cells from smokers and nonsmoker individuals

Microarray and qRT-PCR analyses showed lower expression of miR-1246 in smoker individuals compared to nonsmokers. In the same study, ACE2 mRNA was upregulated in smokers [51] miR-125b Cell culture (HK-2 and HEK-293T) Cells treated with high concentrations of glucose (30 mM) had higher expression of miR-125b and lower ACE2 expression. ROS production and apoptosis in high glucose conditions are partially dependent on miR-125b expression, as its inhibition caused lower ROS production and fewer apoptotic cells [156] miR-421 Cell culture (HEK293T, Huh7, isolated cardiac myofibroblasts) miR-421 upregulation caused specific ACE2 protein downregulation. miR-421 is highly expressed in the kidney; HEK293T cells have higher expression than Huh7 or isolated cardiac myofibroblasts [157] Chronic kidney disease, haemodialysis and control patients; cell culture (THP1) miR-421 levels are higher in the serum from patients with kidney disease. miR-421 serum levels are inversely correlated with ACE2 expression in the leukocytes. THP1 cells exposed to uremic toxins increase miR-421 and decrease ACE2 expression [158] miR-143 Female Wistar rats Rats subjected to mild-and high-intensity training presented higher left ventricle expression of ACE2, Ang (1-7), and Ang (1-7)/AngII ratio, while decreased miR-143 was observed in the left ventricle of the heart of the high-intensity group compared to the sedentary and mild-intensity groups [159] Male SHR and Wistar-Kyoto rats SHR rats subjected to moderate-intensity training showed higher ACE2 protein expression and decreased mi-143 in the aorta [160] and H3 acetylation concomitantly with reduced H3 acetylation in the ACE2 promoter. 148 Cell culture (HTR-8/SVNeo) Cell proliferation was decreased following transfection with miR-483-3p mimic [162] miR-429 FVB/NJ mice Female offspring of maternal low-protein diet (MLPD) fed mice presented higher miR-429, while the male offspring presented the inverse trend compared to the offspring of normal diet-fed mice. ACE2 protein expression was lower in the MLPD female offspring [163] and in 77, 154 Smoking may also be relevant due to miRNA modulation. 51 Inflammation, important in SARS-CoV-2 infection, influences ACE2 expression as previously described. 82, [89] [90] [91] 176 It was shown that NF-κB activation due to viral and bacterial stimuli impairs ACE2 expression via miRNA regulation. 152 The same miRNA - 148, 149, 151 Atorvastatin, which increased H3 acetylation in the ACE2 locus and its expression in rabbits, could be a promising drug to help treat COVID-19. 148 There is a registered clinical trial (NCT04380402) to study the effects of atorvastatin administration in COVID-19 patients but no results were published yet. rhACE2 is also promising since it could, in addition to potentially rescue ACE2 activity loss in the SARS-CoV-2 infection, regulate the levels of histone modifiers and promote beneficial metabolic outcomes. 149 However, there is not a conclusive study evaluating whether variations in non-coding RNAs, DNA methylation and histone PTMs targeting ACE2 are important in COVID-19 patients.

In addition to underlying conditions playing a role in ACE2 epigenetic regulation, it was shown that coronaviruses are able to induce expression changes through epigenetic mechanisms in cell culture. 177 Remarkably, interferon-stimulated genes (ISGs) -ACE2 is an ISG -are differentially modulated by respiratory viruses through histone PTMs and DNA methylation. 50, 177, 178 Indeed, a mice model expressing human ACE2 (hACE2) in its membranes infected with SARS-CoV-2 revealed that genes related to the cellular response to type I interferon and type I interferon signalling pathway are upregulated as short as 3 days after infection. 179 This study also showed that the infection is able to regulate DNA methylation in an organ-specific manner.

However, it remains to be determined the factors and pathways that modulate the epigenetic mechanisms in viral infections and whether ACE2 is epigenetically regulated by SARS-CoV-2 in humans. 

for the Asian Critical Care Clinical Trials Group. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations

Coronavirus: update related to the current outbreak of COVID-19

The presence of SARS-CoV-2 RNA in feces of COVID-19 patients

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Detection of SARS-CoV-2 in different types of clinical specimens

Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Covid-19: four fifths of cases are asymptomatic, China figures indicate

A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

Landscape of X chromosome inactivation across human tissues

Identification of an alternative 5 0 -untranslated exon and new polymorphisms of angiotensinconverting enzyme 2 gene: lack of association with SARS in the Vietnamese population

ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus

Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase

Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS

Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters

Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas

Angiotensin converting enzyme 2: SARS-CoV-2 receptor and regulator of the reninangiotensin system

Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease

Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues

Angiotensin-converting enzyme 2 metabolizes and partially inactivates Pyr-Apelin-13 and Apelin-17: physiological effects in the cardiovascular system

Biased signaling favoring gi over beta-arrestin promoted by an apelin fragment lacking the Cterminal phenylalanine

Apelin is a positive regulator of ACE2 in failing hearts

ACE2 in the second act of COVID-19 syndrome: peptide dysregulation and possible correction with oestrogen

Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity

A protein complex in the brush-border membrane explains a Hartnup disorder allele

Collectrin and ACE2 in renal and intestinal amino acid transport

Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Structural and functional basis of SARS-CoV-2 entry by using human ACE2

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Cell entry mechanisms of SARS-CoV-2

Structure, function, and evolution of coronavirus spike proteins

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein

ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population

Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism

Population-specific ACE2 single-nucleotide polymorphisms have limited impact on SARS-CoV-2 infectivity in vitro

Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2

Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

Electronic address: lung-network@humancellatlas. org; HCA Lung Biological Network. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues

Expression of the SARS-CoV-2 ACE2 receptor in the human airway epithelium

SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells

scRNA-seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS-COV-2 infection in spermatogonia, leydig and sertoli cells

Angiotensin-converting enzyme 2 in the rostral ventrolateral medulla regulates cholinergic signaling and cardiovascular and sympathetic responses in hypertensive rats

Does COVID19 infect the brain? If so, smokers might be at a higher risk

Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

Extrapulmonary manifestations of COVID-19

Identifying airborne transmission as the dominant route for the spread of COVID-19

Multisystem inflammatory syndrome in children: a systematic review

Peripheral nervous system manifestations associated with COVID-19

COVID-19 and multiorgan failure: a narrative review on potential mechanisms

Age-and gender-related difference of ACE2 expression in rat lung

Sex-specific changes in renal angiotensin-converting enzyme and angiotensin-converting enzyme 2 gene expression and enzyme activity at birth and over the first year of life

Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17β-oestradiol-dependent and sex chromosome-independent

Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells

Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD

ACE2 expression is elevated in airway epithelial cells from older and male healthy individuals but reduced in asthma

Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis

Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis

The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects

Predictors of adverse prognosis in COVID-19: a systematic review and meta-analysis

Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications

Smoking is associated with COVID-19 progression: a meta-analysis

Current smoking is not associated with COVID-19

Smoking and COVID-19: what we know so far

Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependent axis

A human long non-coding RNA ALT1 controls the cell cycle of vascular endothelial cells via ACE2 and cyclin D1 pathway

Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells

Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis

HIF-1α, and COVID-19: from pathogenic factors to potential therapeutic targets

ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma-implications for COVID-19

Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress

Hyperoxia downregulates angiotensin-converting enzyme-2 in human fetal lung fibroblasts

ACE2/Ang 1-7 axis: a critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity

Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease

Characterization of ACE and ACE2 expression within different organs of the NOD mouse

Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes

Discrepancy between intrarenal messenger RNA and protein expression of ACE and ACE2 in human diabetic nephropathy

Interaction between TGF-β and ACE2-Ang-(1-7)-Mas pathway in high glucose-cultured NRK-52E cells

Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells

NF-kappaB-dependent increase in intrarenal angiotensin II induced by proteinuria

COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness

Myocardial infarction increases ACE2 expression in rat and humans

Angiotensin-converting enzyme 2-Angiotensin 1-7/1-9 system: novel promising targets for heart failure treatment

Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2

Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats

Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients

Ligand to PPARγ, improves blood pressure and vascular function through renin-angiotensin system regulation

The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucosecontrolled diabetic rat hearts. Heart Vessels

Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors

Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers

COVID-19, ACE2, and the cardiovascular consequences

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19

SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Human recombinant soluble ACE2 in severe COVID-19

The two faces of ACE2: the role of ACE2 receptor and its polymorphisms in hypertension and COVID-19

Interactions among related genes of renin-angiotensin system associated with type 2 diabetes

New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis

Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies

The ACE2 gene: its potential as a functional candidate for cardiovascular disease

Gingival crevicular fluid and serum levels of resistin in obese and non-obese subjects with and without periodontitis and association with single nucleotide polymorphism at -420

SARS-CoV-2 and COVID-19: the most important research questions

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome

Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in south Xinjiang

Association of angiotensinconverting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: a case-control study

The science underlying COVID-19: implications for the cardiovascular system

COVID-19 and comorbidities: deleterious impact on infected patients

Angiotensinconverting enzyme 2 (ACE2) haplotypes are associated with pulmonary disease phenotypes in sarcoidosis patients

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence

Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers

Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study

Tissue-specific expression and regulation of sexually dimorphic genes in mice

Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome

The physiological mechanisms of the sexbased difference in outcomes of COVID19 infection

Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones

Covid-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. might the double x-chromosome in females be protective against SARS-COV-2 compared to the single x-chromosome in males

Gene polymorphisms in angiotensin I converting enzyme (ACE I/D) and angiotensin II converting enzyme (ACE2 C-->T) protect against cerebral malaria in Indian adults

Basic concepts of epigenetics

Non-coding RNAs: classification, biology and functioning

Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy

DNA methylation in mammals

Perinatal exposure to western diet programs autonomic dysfunction in the male offspring

Preliminary analysis of the association between methylation of the ACE2 promoter and essential hypertension

Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients

DNA methylation and mRNA and micro-RNA expression of SLE CD4+ T cells correlate with disease phenotype

Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis

SARS-CoV-2 and systemic lupus erythematosus

Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants

Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications

ACE2 exerts anti-obesity effect via stimulating brown adipose tissue and induction of browning in white adipose tissue

EZH2-mediated H3K27me3 inhibits ACE2 expression

ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19

miRNA-200c-3p is crucial in acute respiratory distress syndrome

MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes

MiRNA let-7b promotes the development of hypoxic pulmonary hypertension by targeting ACE2

microRNA-1246 mediates lipopolysaccharide-induced pulmonary endothelial cell apoptosis and acute lung injury by targeting angiotensin-converting enzyme 2

microRNA-125b contributes to high glucose-induced reactive oxygen species generation and apoptosis in HK-2 renal tubular epithelial cells by targeting angiotensin-converting enzyme 2

Angiotensin-converting enzyme 2 is subject to posttranscriptional regulation by miR-421

Circulating miR-421 targeting leucocytic angiotensin converting enzyme 2 is elevated in patients with chronic kidney disease

Aerobic exercise training-induced left ventricular hypertrophy involves regulatory MicroRNAs, decreased angiotensin-converting enzyme-angiotensin ii, and synergistic regulation of angiotensin-converting enzyme 2-angiotensin (1-7)

Contribution of renin-angiotensin system to exercise-induced attenuation of aortic remodeling and improvement of endothelial function in spontaneously hypertensive rats

Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin-angiotensin system

MicroRNA mimics that target the placental renin-angiotensin system inhibit trophoblast proliferation

Antenatal maternal low protein diet: ACE-2 in the mouse lung and sexually dimorphic programming of hypertension

Therapeutic potential of miRNAs targeting SARS-CoV-2 host cell receptor ACE2

Micro-RNA mimics or inhibitors as antiviral therapeutic approaches against COVID-19

Identification of novel hypothalamic microRNAs as promising therapeutics for SARS-COV-2 by regulating ACE2 and TMPRSS2 expression: an in silico analysis

Integrative analysis of miRNA and mRNA sequencing data reveals potential regulatory mechanisms of ACE2 and TMPRSS2

Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease

COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?

Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19)

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome

Hypertension and hypertensive left ventricular hypertrophy are associated with ACE2 genetic polymorphism

The association between the Angiotensin-Converting Enzyme-2 gene and blood pressure in a cohort study of adolescents

Polymorphisms of angiotensinconverting enzyme 2 gene associated with magnitude of left ventricular hypertrophy in male patients with hypertrophic cardiomyopathy

The trinity of COVID-19: immunity, inflammation and intervention

Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses

MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape

Metabolic reprogramming and epigenetic changes of vital organs in SARS-CoV-2-induced systemic toxicity

Supporting Information section at the end of this article. How to cite this article

ACKNOWLEDGEMENTS RLS and LPCR are research fellows at the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

The authors declare that they have no conflict of interest.

Data sharing is not applicable to this article as no new data were created.

https://orcid.org/0000-0001-7216-6147Luiz Paulo Carvalho Rocha https://orcid.org/0000-0002-6074-5093Paula Rocha Moreira https://orcid.org/0000-0003-1078-6281